Article

Delivery of cell-penetrating chromatin sensor-actuators to human osteosarcoma cells

2020-03-02

Abstract excerpt

<h4>ABSTRACT</h4> The leading FDA-approved drugs for epigenetic cancer therapy are small molecule compounds that activate silenced tumor suppressors by inhibiting enzymes that generate aberrant repressive chromatin. Although promising, this approach is limited because chromatin-modifying enzymes often target non-chromatin proteins and can serve dual functions as gene repressors and activators. Previously, we have...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ff2ebdfd-dd31-58da-a4a8-b8aba6a4dc9e
DOI: 10.1101/2020.02.28.969907

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Delivery of cell-penetrating chromatin sensor-actuators to human osteosarcoma cellsDOI 10.1101/2020.02.28.969907Read

PIC recruitment by synthetic reader-actuators to polycomb-silenced genes blocks triple-negative breast cancer invasionSemantic proximity Read

Non-invasive imaging of cell-based therapies using acoustic reporter genesSemantic proximity Read

Regulation of cancer epigenomes with a histone-binding synthetic transcription factorSemantic proximity Read

A Novel Chromatin-Opening Element for Stable Long-term Transgene ExpressionSemantic proximity Read

Discovery and engineering of hypercompact epigenetic modulators for durable gene activationSemantic proximity Read

Controlling gene activation by enhancers through a drug-inducible topological insulatorSemantic proximity Read

An epigenetic regulator synergizes with alphavirus-mediated gene therapy via biomimetic delivery for enhanced cancer therapySemantic proximity Read

Small-molecule inducible transcriptional control in mammalian cellsSemantic proximity Read

Engineered and Natural Promoters and Chromatin‐Modifying Elements for Recombinant Protein Expression in CHO CellsSemantic proximity Read

<p class="MsoNormal" style="margin-bottom: 12.0pt; text-align: left; mso-line-height-alt: 14.0pt; layout-grid-mode: char; mso-layout-grid-align: none;" align="left">Evaluation of <sup>177</sup>Lu-PSMA-617 Based Targeted Radioligand Therapy with X-Ray Stimulated PSMA Relocation in the <em>PiggyBac</em> Reporter Gene Engineered Orthotopic Prostate Tumor ModelSemantic proximity Read

Development of DuoMYC: a synthetic cell penetrant miniprotein that efficiently inhibits the oncogenic transcription factor MYCSemantic proximity Read

The TAT Protein Transduction Domain as an Intra-articular Drug-Delivery TechnologySemantic proximity Read